Sign in
4

Changes in Ownership

Acrivon Therapeutics, Inc. Filed Acc 0000905148-24-003225

Chief Development Officer gave up 402 shares (to pay taxes)

From the SEC's structured data for this filing

Trades in this filing

Gamelin Erick · Chief Development Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2024-11-14 Shares withheld for taxes : show line 1 in the form −402 $7.92 $3,184 16,961 D
Loading xslF345X05/form4.xml…